JGC
PGNX

J. Goldman & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

J. Goldman & Co’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-211,100
Closed -$1.07M – 386
2019
Q3 		$1.07M Buy
211,100
+11,100
+6% +$55.4K 0.08% 184
2019
Q2 		$1.23M Buy
+200,000
New +$964K 0.09% 181

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

J. Goldman & Co's PGNX Position: Q4 2019 in Review

J. Goldman & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 499,698 shares — an estimated $2.53M sold.

J. Goldman & Co first reported a position in PGNX in Q2 2019 and held it in 2 quarters. The position peaked at $2.53M in Q3 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • J. Goldman & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • J. Goldman & Co sold 499,698 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $2.53M.
  • J. Goldman & Co first reported a position in Progenics Pharmaceuticals Inc in Q2 2019 and held it in 2 quarters.
  • J. Goldman & Co's Progenics Pharmaceuticals Inc position peaked at $2.53M in Q3 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on J. Goldman & Co's 13F filing for Q4 2019, filed 14 Feb 2020.